Becker’s muscular dystrophy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Becker’s muscular dystrophy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Long-term Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy https://clinicaltrials.eu/trial/study-on-the-long-term-effects-of-edg-5506-for-adults-and-adolescents-with-becker-muscular-dystrophy/ Wed, 29 Apr 2026 14:25:46 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-effects-of-edg-5506-for-adults-and-adolescents-with-becker-muscular-dystrophy/ This clinical trial is focused on studying the effects of a medication called EDG-5506 in individuals with Becker Muscular Dystrophy. Becker Muscular Dystrophy is a genetic disorder that causes muscle weakness and wasting over time. The medication being tested, EDG-5506, is taken in the form of a tablet and is designed to help manage symptoms associated with this condition.

The purpose of the study is to assess the long-term safety and effects of EDG-5506 on various health markers and physical abilities in both adults and adolescents who have Becker Muscular Dystrophy. Participants in the study will receive the medication over an extended period, and researchers will monitor their health and any changes in their condition. This includes looking at safety aspects, such as any side effects, and measuring changes in physical and neurological health.

Throughout the study, participants will undergo regular health check-ups, which may include laboratory tests, heart and lung function assessments, and other evaluations to ensure their well-being. The study aims to provide valuable information on how EDG-5506 can be used to support individuals living with Becker Muscular Dystrophy in the long term.

]]> Study on the Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-for-adults-and-adolescents-with-becker-muscular-dystrophy/ Wed, 29 Apr 2026 14:25:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-for-adults-and-adolescents-with-becker-muscular-dystrophy/ This clinical trial is focused on studying a condition called Becker Muscular Dystrophy (BMD), which is a genetic disorder that affects muscle strength and function. The study will evaluate a treatment known as EDG-5506, which is taken in the form of a tablet. The purpose of the study is to assess the safety and effects of EDG-5506 on individuals with BMD, including both adults and adolescents.

Participants in the study will be randomly assigned to receive either the EDG-5506 treatment or a placebo. The study will monitor various health indicators, such as muscle function and certain blood markers, over a period of time. The treatment period can last up to 52 weeks, during which participants will have regular check-ups to ensure their safety and to track any changes in their condition.

The study aims to gather information on how well EDG-5506 works in improving muscle function and its overall safety for people with Becker Muscular Dystrophy. This information could help in developing better treatments for this condition in the future. Participants will be closely monitored for any side effects or changes in their health throughout the study.

]]> Study on the Effects of EDG-5506 in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-in-adults-with-becker-muscular-dystrophy-mcardle-disease-or-limb-girdle-muscular-dystrophy/ Wed, 29 Apr 2026 14:25:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-in-adults-with-becker-muscular-dystrophy-mcardle-disease-or-limb-girdle-muscular-dystrophy/ This clinical trial is focused on studying the effects of a new treatment called EDG-5506 on certain muscle-related diseases. The diseases being studied are Becker Muscular Dystrophy, McArdle Disease, and Limb-Girdle Muscular Dystrophy. These are conditions that affect the muscles, leading to weakness and other symptoms. The treatment being tested, EDG-5506, is taken in the form of a tablet.

The purpose of the study is to understand how EDG-5506 affects markers in the body that indicate muscle damage. Participants in the study will be randomly assigned to receive either the EDG-5506 tablet or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased.

Throughout the study, participants will undergo various assessments to monitor their health and the effects of the treatment. These assessments will include checking for any side effects, measuring changes in muscle-related markers, and evaluating overall health through tests like blood work and physical exams. The study will last for a period of time, during which participants will be closely monitored to gather important information about the safety and effectiveness of EDG-5506.

]]>